乳腺癌幸存者的心力衰竭相关心脏毒性:一个范围审查
Pinyadapat Vacharanukrauh1, Kyle J Miller2, Sheikh M Alif3,4
1Institute of Health and Wellbeing, Federation University Australia, Ballarat, VIC, Australia. pinyadapatareerob@students.federation.edu.au.
Cardio-oncology (London, England)
|December 28, 2025
概括
乳腺癌幸存者面临显著的心力衰竭 (HF) 和死亡风险,通常与像 antracyclines 和 trastuzumab 这样的治疗有关. 早期评估和干预对于管理这种持续的心血管负担至关重要.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 在瘤学瘤学.
- 心血管医学 心血管医学
背景情况:
- 乳腺癌是全球主要的恶性瘤,心血管疾病 (CVD) 是幸存者的主要非癌症死亡原因.
- 关于乳腺癌患者心力衰竭 (HF) 发生率和心脏毒性,现实世界数据有限.
- 本综述解决了对乳腺癌幸存者的心血管结果的综合证据的需求.
研究的目的:
- 综合有关心力衰竭 (HF) 发生率,心血管死亡率和乳腺癌患者全因死亡率的证据.
- 为了绘制乳腺癌幸存者经历的额外心血管结果.
- 确定患有心血管不良事件风险较高的子组.
主要方法:
- 根据乔安娜·布里格斯研究所的方法进行范围审查.
- 包括到2024年7月发表的同行评审的观察性研究.
- 通过PubMed,MEDLINE,CINAHL和Embase进行搜索,使用CASP工具进行双重选和质量评估.
主要成果:
- 15项高质量的队列研究 (N=294-122,217) 显示HF风险显著升高 (HR高达2.71),达到早期峰值并持续.
- 所有原因的死亡率明显高 (HR>3.0),而心血管死亡率的发现是混合的.
- 关键的危险因素包括年龄较小,心脏代谢并发症,晚期,以及暴露于 antracyclines 或 trastuzumab.
结论:
- 乳腺癌幸存者经历了相当大的,长期的心血管负担,特别是关于HF和整体死亡率.
- 强调早期心血管疾病风险评估和心脏保护策略的急需性.
- 强调需要进行大规模的前性研究,以推进精确心脏瘤学和改善生存率.
相关概念视频
01:30Heart Failure VII: Nursing Interventions
392
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
392
01:27Heart Failure I: Introduction
657
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
657
01:29Cardiomyopathy VI: Nursing Management
289
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
289
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
360
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
360
01:29Cardiomyopathy V: Interprofessional Care
310
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
310
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K